Advertisement
CYPH vs SABS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYPH is a Hold and SABS is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CYPH’s FA Score shows that 0 FA rating(s) are green whileSABS’s FA Score has 0 green FA rating(s).
- CYPH’s FA Score: 0 green, 5 red.
- SABS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CYPH’s TA Score shows that 5 TA indicator(s) are bullish while SABS’s TA Score has 4 bullish TA indicator(s).
- CYPH’s TA Score: 5 bullish, 4 bearish.
- SABS’s TA Score: 4 bullish, 6 bearish.
Price Growth
CYPH (@Investment Managers) experienced а +120.50% price change this week, while SABS (@Biotechnology) price change was +2.16% for the same time period.
The average weekly price growth across all stocks in the @Investment Managers industry was +2.12%. For the same industry, the average monthly price growth was +8.00%, and the average quarterly price growth was +4.69%.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.
Reported Earning Dates
SABS is expected to report earnings on Nov 17, 2026.
Industries' Descriptions
@Investment Managers (+2.12% weekly)Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.
@Biotechnology (+3.69% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| CYPH | SABS | CYPH / SABS | |
| Capitalization | 153M | 344M | 44% |
| EBITDA | -56.75M | 2.89M | -1,963% |
| Gain YTD | 22.414 | 1.070 | 2,096% |
| P/E Ratio | 2.20 | 15.71 | 14% |
| Revenue | 0 | 0 | - |
| Total Cash | 6.69M | 107M | 6% |
| Total Debt | 38K | 6.17M | 1% |
CYPH | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 98 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 34 | |
P/E GROWTH RATING 1..100 | 99 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CYPH | SABS | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 90% | N/A |
| Stochastic ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| Momentum ODDS (%) | 3 days ago 80% | 3 days ago 90% |
| MACD ODDS (%) | 3 days ago 89% | 3 days ago 85% |
| TrendWeek ODDS (%) | 3 days ago 87% | 3 days ago 81% |
| TrendMonth ODDS (%) | 3 days ago 86% | 3 days ago 86% |
| Advances ODDS (%) | 3 days ago 89% | 6 days ago 80% |
| Declines ODDS (%) | 10 days ago 90% | 4 days ago 90% |
| BollingerBands ODDS (%) | 3 days ago 90% | 3 days ago 89% |
| Aroon ODDS (%) | N/A | 3 days ago 90% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| IGNIX | 27.75 | 0.50 | +1.83% |
| Nomura Natural Resources I | |||
| OGIIX | 60.03 | 0.41 | +0.69% |
| Invesco Global Opportunities R6 | |||
| WFICX | 18.07 | 0.08 | +0.44% |
| North Star Small Cap Value Institutional | |||
| IVFAX | 5.02 | 0.01 | +0.20% |
| Federated Hermes Intl Strat Val Div A | |||
| OWSMX | 18.49 | N/A | N/A |
| Old Westbury Small & Mid Cap Strategies | |||
CYPH and
Correlation & Price change
A.I.dvisor indicates that over the last year, CYPH has been loosely correlated with INKT. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CYPH jumps, then INKT could also see price increases.
| Ticker / NAME | Correlation To CYPH | 1D Price Change % | ||
|---|---|---|---|---|
| CYPH | 100% | +19.33% | ||
| INKT - CYPH | 42% Loosely correlated | +4.99% | ||
| AXON - CYPH | 40% Loosely correlated | +2.20% | ||
| SABS - CYPH | 36% Loosely correlated | +2.16% | ||
| AMRN - CYPH | 35% Loosely correlated | +0.21% | ||
| ALLR - CYPH | 30% Poorly correlated | -3.40% | ||
More | ||||
SABS and
Correlation & Price change
A.I.dvisor indicates that over the last year, SABS has been loosely correlated with REVB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SABS jumps, then REVB could also see price increases.
| Ticker / NAME | Correlation To SABS | 1D Price Change % | ||
|---|---|---|---|---|
| SABS | 100% | +2.16% | ||
| REVB - SABS | 48% Loosely correlated | +1.87% | ||
| INKT - SABS | 47% Loosely correlated | +4.99% | ||
| CYPH - SABS | 46% Loosely correlated | +19.33% | ||
| TECX - SABS | 35% Loosely correlated | +4.38% | ||
| BEAM - SABS | 32% Poorly correlated | +4.83% | ||
More | ||||